Was Peter Kaiser’s Ocular Therapeutix (OCUL) share sale a discretionary trade?

The filing states the sale was not a discretionary trade by Peter Kaiser. Shares were sold under a durable automatic sale instruction adopted April 9, 2024, to execute a sell-to-cover election for tax withholding on restricted stock units vesting May 22, 2026.

Ocular Therapeutix (NASDAQ: OCUL) CDO executes 2,967-share tax sell-to-cover trade

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Ocular Therapeutix Chief Development Officer Peter Kaiser reported an open-market sale of 2,967 shares of common stock at a weighted average price of $8.20 per share on May 26, 2026, leaving him with 266,141 shares held directly.

According to the disclosure, these shares were sold under a durable automatic sale instruction adopted on April 9, 2024 to execute a sell-to-cover election for tax withholding related to restricted stock units vesting on May 22, 2026. The filing states that the sales do not represent a discretionary trade by Kaiser.

Insider Trade Summary 10b5-1

Net Seller: 2,967 shares ($24,329)

Net Sell 1 txn

Insider Kaiser Peter

Role Chief Development Officer

Sold 2,967 shs ($24K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,967	$8.20	$24K

Holdings After Transaction: Common Stock — 266,141 shares (Direct, null)

Footnotes (1)

Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2026. The sales do not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.1549 to $8.2550, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Key Figures

Shares sold: 2,967 shares Weighted average sale price: $8.20 per share Post-transaction holdings: 266,141 shares +4 more

7 metrics

Shares sold 2,967 shares Open-market sale on May 26, 2026

Weighted average sale price $8.20 per share Common stock sale

Post-transaction holdings 266,141 shares Common stock held directly after sale

Price range of trades $8.1549–$8.2550 per share Multiple transactions within reported sale

Net shares sold 2,967 shares Net-sell direction in transaction summary

Instruction adoption date April 9, 2024 Durable automatic sale instruction adoption

RSU vesting date May 22, 2026 Restricted stock units triggering tax withholding

Key Terms

durable automatic sale instruction, sell-to-cover election, restricted stock units, weighted average price, +1 more

5 terms

durable automatic sale instruction financial

"sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024"

sell-to-cover election financial

"effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations"

restricted stock units financial

"tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

05/28/2026 - 04:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaiser Peter

(Last)

(First)

(Middle)

C/O OCULAR THERAPEUTIX, INC.

14 CROSBY DRIVE, 3RD FLOOR

(Street)

BEDFORD

MASSACHUSETTS

01730

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/26/2026		S⁽¹⁾		2,967⁽¹⁾	D	$8.2⁽²⁾	266,141	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2026. The sales do not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.1549 to $8.2550, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

	/s/ Todd Anderman, Attorney-in-Fact for Peter Kaiser	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Ocular Therapeutix (OCUL) executive Peter Kaiser report in this Form 4?

Peter Kaiser reported selling 2,967 shares of Ocular Therapeutix common stock. The transaction was an open-market sale under a pre-established instruction, primarily to cover tax withholding obligations tied to vesting restricted stock units rather than a discretionary stock sale.

At what price did Peter Kaiser’s Ocular Therapeutix (OCUL) shares sell?

The reported weighted average sale price was $8.20 per share. The filing notes that individual trades occurred in multiple transactions at prices ranging from $8.1549 to $8.2550, and detailed breakdowns are available upon request from the company or the SEC staff.

How many Ocular Therapeutix (OCUL) shares does Peter Kaiser hold after this transaction?

After selling 2,967 shares, Peter Kaiser directly holds 266,141 shares of Ocular Therapeutix common stock. This indicates the sale represented a small portion of his overall direct holdings as disclosed in this Form 4 filing with the Securities and Exchange Commission.

Why were Ocular Therapeutix (OCUL) shares sold in this Form 4 filing?

Shares were sold to satisfy tax withholding obligations from vesting restricted stock units. The transaction executed a sell-to-cover election under a durable automatic sale instruction, meaning it was a pre-planned mechanism for taxes rather than a voluntary change in Kaiser’s investment exposure.

What trading range did Peter Kaiser’s Ocular Therapeutix (OCUL) sale cover?

The weighted average price of $8.20 reflects multiple trades between $8.1549 and $8.2550 per share. The filing notes Kaiser will provide full details of share counts at each price within this range to the company, its security holders, or SEC staff upon request.